The Effect of Psoriasis on Patients' Quality of Life and Improvements Associated with Alefacept Therapy

Abstract

Patients with psoriasis may experience impaired psychosocial mental status regardless of their objectively defined disease severity. The objective clinical measures of disease that are commonly used to evaluate a patient's psoriasis fail to take into account the effect of psoriasis on patients' quality of life (QOL). As a result, a significant number of patients are dissatisfied with conventional treatments and are searching for new options. A high unmet need for effective and safe long-term therapies that can also improve patients' QOL exists in psoriasis. Alefacept, a selective biologic agent specifically designed for the treatment of psoriasis, provides improvement in both the physical (as measured by the Psoriasis Area and Severity Index) and mental (as measured by the Dermatology Life Quality Index) aspects of the disease. Additionally, alefacept is extremely well tolerated, with no negative effect on QOL, and the improvement in QOL is maintained off-treatment, which is consistent with its remittive effects on the disease. Alefacept helps fulfill the needs of psoriasis patients by providing efficacy, safety, off-treatment remissions, and improvement in QOL.

Get full access to this article

View all access options for this article.

References

Krueger

Koo

Lebwohl

. The impact of psoriasis on quality of life. Arch Dermatol 2001; 137:280–284.

Rapp

Feldman

Exum

. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41:401–407.

Salonen

, on behalf of the EUROPSO Patient Survey Study Group. EUROPSO psoriasis patient survey: First results from 17 990 association members with psoriasis. Poster presented at the 1st Spring European Academy of Dermatology and Venereology Symposium, 27 February-1 March 2003, St Julian's, Malta.

Salonen

, on behalf of the EUROPSO Patient Survey Study Group. The EUROPSO psoriasis patient survey: Treatment history and satisfaction. Poster presented at the 1st Spring European Academy of Dermatology and Venereology Symposium, 27 February-1 March 2003, St Julian's, Malta.

Akay

Pekcanlar

Bozdag

. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Eur Acad Dermatol Venereol 2002; 16:347–352.

Gupta

Schork

Gupta

. Suicidal ideation in psoriasis. Int J Dermatol 1993; 32:188–190.

Gupta

. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139:846–850.

Finlay

Salek

Haney

, for the Alefacept Clinical Study Group. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003; 206:307–315.

Thalji

Haggerty

Rubin

. National Survey of Functional Health Status: Final Report, National Opinion Research Center, Chicago 1990.

10.

Tarlov

Ware

Jr Greenfield

. The Medical Outcomes Study. An application of methods for monitoring the results of medical care. JAMA 1989; 262:925–930.

11.

Marks

Barton

Shuttleworth

. Assessment of disease progress in psoriasis. Arch Dermatol 1989; 125:235–240.

12.

van de Kerkhof

. On the limitations of psoriasis area and severity index (PASI). Br J Dermatol 1992; 126:205.

13.

Kirby

Richards

Woo

. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001; 45:72–76.

14.

Fortune

Main

O'Sullivan

. Quality of life in patients with psoriasis: The contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997; 137:755–760.

15.

Krueger

Feldman

Camisa

. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?. J Am Acad Dermatol 2000; 43:281–285.

16.

Callen

Krueger

Lebwohl

. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003; 49:897–899.

17.

Koo

Menter

. The Koo-Menter Psoriasis Instrument for identifying candidate patients for systemic therapy. Poster 45 presented at the Summer Academy of the American Academy of Dermatology, 25–29 July 2003, Chicago, IL.

18.

Lebwohl

Christophers

Langley

, for the Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139:719–727.

19.

Krueger

Papp

Stough

, for the Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47:821–833.

20.

Feldman

Menter

Koo

. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004; 150:317–326.

21.

van de Kerkhof

Vaishnaw

Kragballe

. Alefacept is efficacious in a broad spectrum of patients with psoriasis. Poster presented at the 1st Spring European Academy of Dermatology and Venereology Symposium, 27 February–1 March 2003, St Julian's, Malta.

22.

Carlin

Feldman

Krueger

. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50:859–866.

23.

Menter

Cather

. Long-term use of alefacept: Safety and off-treatment responses in patients who have received multiple courses of therapy. Poster presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC.